Medium materiality5/10
PacBio price target raised to $2.50 from $1.50 at Stephens
Why it may matterVerify against the original reporting
Bullish target revision, tempered by the fact that it is a single analyst estimate.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Stephens raised its PACB price target by $1.00, from $1.50 to $2.50. The new target is about 22% above the posted price of $2.05; this is an analyst opinion rather than a guaranteed outcome.
- Stephens raised its PACB target to $2.50 from $1.50, about 22% above the posted $2.05 price.
Key facts
- 01
Target: $2.5
- 02
Posted price: $2.05
- 03
Analyst firm: Stephens
- 04
Analyst: Mason Carrico
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.